Propanc Biopharma (PPCB) Investor presentation summary

Leadership and expertise

• Executive team has over 25 years of experience in oncology drug development, clinical pharmacology, and finance.

• Scientific advisory board includes experts in anatomy, translational cancer research, and tumorigenic models.

Market opportunity and unmet need

• Targeting pancreatic and ovarian cancers with a combined addressable market of $14.3B and a long-term focus on metastatic solid tumors (~$111B TAM).

• 91% of cancer cases are solid tumors, with significant mortality in pancreatic and ovarian cancers.

Product pipeline and technology

• Lead candidate PRP is a synergistic combination of trypsinogen and chymotrypsinogen, with a unique mechanism converting cancerous cells back to healthy cells.

• Compassionate use data in 46 terminal patients showed 41% exceeded life expectancy, with no serious adverse events.

• Phase 1b clinical study in 30–40 patients is planned, with results expected in 2026.

• Synthetic recombinant version (Rec-PRP) is entering preclinical development.